Bu Yin is a patent agent in the firm’s San Diego office. Dr. Yin prepares and prosecutes domestic and international patent applications in biotechnology, pharmaceuticals and life sciences. He has experience in conducting due diligence assessments, freedom to operate analyses, and patentability analyses. He has also provided support for patent litigation, patent arbitration, and third-party preissuance submission.
Dr. Yin’s scientific expertise encompasses the fields of biochemistry, cell and molecular biology, and genetics/epigenetics. He is familiar with recombinant DNA and protein, therapeutic antibodies, neurodegenerative diseases, cancer diagnosis and therapy, vaccines and gene therapy, high-throughput drug discovery, and drug delivery systems, amongst other subject matters.
Dr. Yin was a Presidential Postdoctoral Fellow at the Novartis Institutes for Biomedical Research in Cambridge, Massachusetts. At Novartis, he developed high-throughput si/shRNA-based screening technologies to study cancer cell death. Dr. Yin earned his Ph.D. in Cell and Molecular Biology from the University of Pennsylvania, working in the Children’s Hospital of Philadelphia. His research focused on DNA damage and repair during B-cell and T-cell development, during antibody production and immune responses, and during tumorigenesis. Dr. Yin received his B.S. from Tsinghua University, Beijing, China, with training in bioinformatics at Uppsala University, Sweden. Prior to joining the firm, Dr. Yin was a registered patent agent at another international law firm.
Dr. Yin is an author of scientific publications in leading journals including Nature Immunology, Molecular Cell, and Journal of Clinical Investigation. He also serves as a reviewer for many international journals. He was a recipient of the Saul Winegrad Award for Outstanding Dissertation from the University of Pennsylvania, Emphasis in Tumor Immunology Training Grant from the Cancer Research Institute, New York, and the Aflac Inc. Scientist-in-training Award from the American Association for Cancer Research.
Dr. Yin is fluent in Mandarin Chinese.
©1996-2017 Morrison & Foerster LLP. All rights reserved.